December 29, 2011 — Medrad Inc. recently released the Certegra Informatics Connect.RIS vendor-neutral informatics application. The system establishes connectivity between Medrad's Stellant contrast-injection systems, and hospital radiology reporting systems and radiology information systems (RIS).  

The Connect.RIS application auto-populates contrast-injection records into radiology reporting systems and RIS, eliminating the need for radiologists to look-up or dictate contrast-injection records. In addition, the application delivers consistent patient records throughout facilities, and supports accurate and efficient billing and reconciliation processes.

Connect.RIS is part of the Certegra informatics platform, Medrad’s Contrast Dose Management solution. Certegra is comprised of a comprehensive line of products designed to support radiology professionals' clinical and administrative needs. The applications automatically document and integrate computed tomography (CT) contrast-injection records across clinical systems – using the injector as the source. Injector-based P3T software individualizes contrast protocols at the point-of-care. Certegra products work in any combination with Medrad's Stellant contrast-injection systems.

Additional Certegra software and applications include:

  • Manage.Report Application (data-driven reporting and analysis across CT suites and shifts):
    • Continually measures and helps radiology professionals actively manage performance department-wide
    • Helps to identify and uncover root cause of atypical events, re-scans and more
  • Connect.PACS application (PACS integration):
    • Automatically captures and integrates CT contrast-injection records (including the protocols programmed and delivered) into picture archiving and communications systems (PACS)
    • Provides radiologists new information concerning the contrast-injections associated with clinical images as they read
    • Allows radiologists to relate their evaluation of clinical images to any changes made at the point-of-care to the protocol prescribed
  • P3T software line (personalized CT contrast protocols for abdomen, cardiac and pulmonary angiography studies):
    • Enables consistent protocol optimization across patient populations and simplifies complex study administration
    • Enables a higher percentage of diagnostic studies and reduces the potential for unnecessary rescans

For more information: www.medrad.com


Related Content

News | Radiology Imaging

Aug. 13, 2026 — Epic's new Care Everywhere Diagnostic Image Exchange allows health systems using Epic to share ...

Time August 21, 2026
arrow
News | Cardiac Imaging

Aug. 20, 2026 – The novel, radiopaque, polymer-based embolic coil from Embolization, Inc. has now surpassed 125 implants ...

Time August 20, 2026
arrow
News | Breast Imaging

Aug. 13, 2026 – Perimeter Medical Imaging AI recently announced that Intermountain Health, the largest nonprofit health ...

Time August 14, 2026
arrow
News | Cardiac Imaging

Aug. 11, 2026 — Bracco Imaging recently announced that VueJect, its dedicated ultrasound contrast delivery system ...

Time August 12, 2026
arrow
News | Lung Imaging

Aug. 11, 2026 — Noah Medical has launched the Galaxy II software, the next evolution of its robotic-assisted ...

Time August 10, 2026
arrow
News | Radiology Business

Aug. 4, 2026 — Canon Medical Systems USA (CMSU) has appointed Tsuneo "Neo" Imai as president and chief executive officer ...

Time August 10, 2026
arrow
Feature | Artificial Intelligence | Kyle Hardner

Could the era of the empowered patient change how imaging reports are structured and presented? It’s a question on the ...

Time August 03, 2026
arrow
News | PACS

July 8, 2026 — Freeland Systems, a cloud PACS and clinical imaging software company, has launched its new customer ...

Time July 10, 2026
arrow
News | Radiology Imaging

June 15, 2026 — Lead Glass Pro, a supplier of radiation shielding products, has expanded its turnkey installation ...

Time June 18, 2026
arrow
News | Contrast Agents

June 15, 2026 – Bayer has announced that the U.S. Food and Drug Administration (FDA) approved Ambelvist (gadoquatrane) ...

Time June 16, 2026
arrow
Subscribe Now